Our production line and Capacity
Production of peptide drugs API
reputable pharmaceutical companies have produced more than sixty types of peptide in the form of drugs and made them available globally. Given their great potency, low risk and side effects, as well as their appropriate therapeutic results, the use of peptide drugs in the form of new medications is increasing today. Since 2007, the rate of peptide drug approvals in the Food and Drug Administration (FDA) of the United States has been twice as other drugs. As far as the peptide products are concerned, the services and products of Biosun Pharmed Company involve the synthesis of Eptifibatide and Octreotide drugs. But in the company's vision plan, this product portfolio for the family of peptide drugs will reach more than twelve peptide medications.
Production of hazardous (high-risk) drugs
Hazardous and high potent drugs are referred to drugs whose very small amounts may cause complications including pharmacological effects, carcinogenicity, teratogenicity, disturbance in the reproductive system, toxicity in body organs small doses, and genetic toxicity. In general, the high toxicity of high-risk and hazardous drugs and legal requirements for their production, analysis and maintenance of are among the main constraints on the production of such drugs, requiring special equipment. This has limited the number of manufacturers of such drugs.
Using the most advanced manufacturing machinery and isolator technology for all stages of production, Biosun Pharmed Company has been able to manufacture these drugs in accordance with cGMP and other standards of the day.
In addition to maintaining product quality, the company's technologies also guarantee the safety and health of employees and environmental protection. The company's measures to protect employee health and the environment include the use of standard leveled areas and the provision of a SIP and CIP fully-mechanized washing and sterilization system to prevent staff exposure to drug remnants. Biosun Pharmed Company produces these products in vial and pre-filled syringes (PFS), in liquid and freeze-dried forms. In addition, since employee safety and health is a top priority of Biosun Pharmed Company, a support committee has been formed in the company's manufacturing centers to enhance employee safety and protect the environment. The HSE guidelines have been drawn up based on the latest international rules and are implemented at the manufacturing and research and development centers. These guidelines include: HSE system management, manufacturing safety, crisis management and accident reporting, health monitoring, limitation of occupational exposure to chemicals, and provision of necessary equipment to maintain and protect the health and safety of individuals, products and the environment.
The production of biosimilar drugs API in four distinct lines
Using the state-of-the-art knowledge, approved standard equipment by international authorities, and fully-automatic filling lines in our biosimilar project, a batch of products, called biochemical products, is produced and supplied to the market. Taking advantage of experienced experts, this will guarantee a bright future for the Biosun Pharmed Company in the domestic and international markets. In the biosimilar formulation and filling section of this company, various types of biochemical and monoclonal antibodies required by domestic and foreign markets are produced in a variety of forms, such as vials, syringes and cartridges, and are marketed after final packaging.
- Specific vaccine product line
Currently, DTP-HepB-Hib vaccine (Pentavalent) is available in ready-made infusion syringes (PFS). Using the filling line of Biosun Pharmed Company in the Barakat Pharmaceutical Town, it will also be possible to fill the vaccine in vials. Accordingly, the company will not only provide about 6 million doses of Pentavalent vaccine (needed in the country), but also will have the capability to multiply its production capacity for export to the countries of the region.
- Vial filling lines, prefilled syringes (PFS) and cartridges
Biosun Pharmed Company and Barakat Pharmaceutical Holding Co. have done extensive work on vaccine production and are the only manufacturer of DTP-HepB-Hib vaccine (Pentavalent) in Iran. Using the state-of-the-art equipment, sufficient production knowledge and dedicated manpower, it is hoped that Biosun Pharmed Company will have a significant share of domestic and foreign markets in the near future.